Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Particip...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2007

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/26225

Acceso en línea:

https://doi.org/10.1016/j.ophtha.2006.12.028
https://repository.urosario.edu.co/handle/10336/26225

Palabra clave:

Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Diabetic Retinopathy
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Middle Aged
Ophthalmoscopy
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body

Rights

License

Restringido (Acceso a grupos específicos)